Skip to content

Double-blind, randomized, placebo-controlled pilot clinical trial to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2 macrophages and fat-derived mesenchymal cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV)

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-507700-32-00
Acronym
PRSCK-21P01
Enrollment
50
Registered
2024-01-22
Start date
2024-10-02
Completion date
Unknown
Last updated
2026-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV)

Interventions

None listed

Sponsors

Peaches Biotech S.L.
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026